

CORPORATE PROFILE


Alimera is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations.

6120 Windward Parkway, Suite 290
 Alpharetta, GA 30005
 Phone: 1 (844) 445-8843
 Fax: (678) 990 5744
<https://alimerasciences.com>
info@alimerasciences.com

John Marco, CORE IR
 377 Oak Street
 Garden City, NY 11530
 Phone: 516-222-2560
 E-mail: johnm@coreir.com
www.coreir.com

STOCK PERFORMANCE

Symbol	alim
Exchange	NSD
Market Cap.	19.91m
52 Week Range	0.0045 - 15.90
Close	4.05
Volume	6
Shares Outstanding	4,965,949
As of Apr 9, 2020 4:00 pm	



MANAGEMENT TEAM

Rick Eiswirth – President and Chief Executive Officer

Philip Ashman – COO, Senior VP, Commercial Operations Europe

Dave Holland – CMO, Senior VP Corporate Communications & Managed Markets

Phil Jones – Chief Financial Officer

Samer Kaba M.D – Chief Medical Officer

BOARD OF DIRECTORS

Rick Eiswirth – President and Chief Executive Officer, Alimera Sciences

Brian Halak, Ph.D., B.S.E. – Partner at Domain Associates, L.L.C. and CEO of WindMIL Therapeutics

Garheng Kong, M.D., Ph.D – Managing Partner, Sofinnova HealthQuest

James R. Largent, M.B.A. – Lead Independent Director

Dan Myers – Non-Executive Chairman of the Board, interim CEO of Leo Lens Pharma

Peter J. Pizzo, III – Chief Financial Officer, ControlRad

John Snisarenko – Chief Commercial Officer, Oyster Point Pharma

Mary T. Szela, M.B.A., B.S.N. – Chief Executive Officer and President, Surefire Medical, Inc.

RECENT HEADLINES

[Mar 31, 2020 - Alimera Sciences Appoints Steven T. Gill to the Newly Created Position of Vice President, Thought Leader Engagement](#)

[Mar 25, 2020 - Alimera Sciences Data Available for the 11th Annual Congress on Controversies in Ophthalmology: Europe Virtual Conference](#)

[Feb 27, 2020 - Alimera Sciences Inc \(ALIM\) Q4 2019 Earnings Call Transcript](#)

[Feb 26, 2020 - Alimera Sciences Reports Record Fourth Quarter and 2019 Results](#)

[Feb 24, 2020 - Alimera Sciences Meets Revenue Milestone and Accesses Additional \\$2.5 Million Under Solar Debt Agreement](#)